The AAA ATPase spastin links microtubule severing to membrane modelling  by Lumb, Jennifer H. et al.
Biochimica et Biophysica Acta 1823 (2012) 192–197
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrReview
The AAA ATPase spastin links microtubule severing to membrane modelling☆
Jennifer H. Lumb, James W. Connell, Rachel Allison, Evan Reid ⁎
Department of Medical Genetics and Cambridge Institute for Medical Research, University of Cambridge, UK☆ This article is part of a Special Issue entitled: AAA A
⁎ Corresponding author at: Department of Medical Ge
Medical Research, Wellcome Trust/MRC Building, Adde
CB2 0XY, UK. Tel.: +44 1223 762602; fax: +44 1223 7
E-mail address: ealr4@cam.ac.uk (E. Reid).
0167-4889/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2011.08.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 June 2011
Received in revised form 10 August 2011
Accepted 17 August 2011







Hereditary spastic paraplegiaIn 1999, mutations in the gene encoding the microtubule severing AAA ATPase spastin were identiﬁed as
a major cause of a genetic neurodegenerative condition termed hereditary spastic paraplegia (HSP). This
ﬁnding stimulated intense study of the spastin protein and over the last decade, a combination of cell biolog-
ical, in vivo, in vitro and structural studies have provided important mechanistic insights into the cellular
functions of the protein, as well as elucidating cell biological pathways that might be involved in axonal
maintenance and degeneration. Roles for spastin have emerged in shaping the endoplasmic reticulum and
the abscission stage of cytokinesis, in which spastin appears to couple membrane modelling to microtubule
regulation by severing. This article is part of a Special Issue entitled: AAA ATPases: structure and function.TPases: structure and function.
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In 1999, mutations in the gene encoding the microtubule (MT)
severing AAA ATPase spastin were identiﬁed as a major cause of a
genetic neurodegenerative condition termed hereditary spastic para-
plegia (HSP) [1]. HSP is a disease in which there is a selective distal
axonopathy involving the longest axons of the main central nervous
system pathway that controls voluntary movement, the corticospinal
tract (reviewed in [2–5]). This ﬁnding stimulated intense study
of the spastin protein and over the last decade a combination of cell
biological, in vivo, in vitro and structural studies have provided impor-
tant mechanistic insights into the cellular functions of the protein, as
well as elucidating cell biological pathways that might be involved in
axonal maintenance and degeneration. These advances are reviewed
in this article.
1.1. Overview of the domain organisation of spastin
Like many other AAA proteins, spastin has a modular domain
organisation (Fig. 1). The C-terminal of the protein contains domains
involved in microtubule severing. These include the AAA ATPase
domain, which catalyses microtubule severing, and the microtubule
binding domain (MTBD), which is necessary for the protein to bind
microtubules before severing can occur. In contrast, domains in theN-terminal half of the protein are involved in targeting spastin to
speciﬁc sites of action, often by binding to various adaptor proteins
(Fig. 1). In the case of some adaptors, the precise binding domains
used are not yet clearly characterised. However, these N-terminal
targeting domains include a hydrophobic domain (HD) that is predicted
to form a hairpin loop membrane domain, and an MIT (present in
microtubule interacting and trafﬁcking proteins) domain, both of
which are discussed in more detail below.
A feature adding complexity to understanding the cellular roles of
spastin is that in mammalian cells it has 4 main isoforms (Fig. 1) [6,7].
The 616 amino acid full-length (M1) protein is produced by transla-
tion from the ﬁrst start codon in exon 1 of the gene. A shorter isoform
lacking the ﬁrst 86 amino acids of the full-length protein (M87 spastin)
is produced by a combination of alternative initiation of translation
from a second start codon in the M1 transcript, and translation from
an M87-speciﬁc shorter transcript that is driven by a cryptic promotor
in exon 1 of the gene [6,7]. The M87 isoform is the most abundant in
all tissues examined so far [7]. Importantly, this form of the protein
lacks the HD, and the functional consequences of this are discussed in
more detail below. In addition, variants of both M1 and M87 spastin
that lack a 32-amino acid stretch encoded by exon 4 are also present.
The role of this 32-amino acid region is unknown.
Spastin has a complex subcellular localization and this is at least
partly explained by sequence differences between different spastin
isoforms. The M1 isoform is predominantly localised on the early
secretory pathway, at the endoplasmic reticulum (ER) and possibly
also at the very early ER-to-Golgi intermediate compartment [8].
The HD is important for this localization. In contrast, the M87 iso-
form exists in a cytosolic pool, shows partial co-localisation with mi-
crotubules, and can be recruited to endosomes and to the cytokinetic
Fig. 1. Spastin domain organisation and veriﬁed binding partners. HD-hydrophobic domain, MIT = MIT domain, MTBD = microtubule binding domain. The dashed line indicates
the approximate position of amino acid M87.
193J.H. Lumb et al. / Biochimica et Biophysica Acta 1823 (2012) 192–197midbody during cell division, in an MIT-domain-dependent manner
[8]. The M87 isoform has also been reported in the nucleus, and its
sequence contains two nuclear localization signals [6,9]. Functions
of spastin in the nucleus are unknown.
1.2. Spastin severs microtubules
Shortly after the spastin gene was identiﬁed, it was recognised
that spastin protein had sequence similarity to katanin, an AAA
ATPase which was known to be involved in microtubule severing
[10]. Studies in mammalian cells suggested that spastin was involved
in microtubule dynamics, since ATPase-defective forms of spastin
over-expressed in cultured cells bound and bundled microtubules,
whilst expression ofwild-type spastin led to disassembly of themicro-
tubule network [10]. The idea that spastin was a microtubule severing
protein was strongly supported by subsequent studies in a variety of
different model systems, which, for example, showed that puriﬁed
spastinwas sufﬁcient to causemicrotubule breakage in permeabilised,
cytosol-depleted cultured cells, and that recombinant mammalian or
Drosophila spastin was able to sever microtubules in vitro [11–13].
Findings from in vivo model systems were also consistent with a
role for spastin in microtubule regulation. In ﬂies, over-expression of
spastin in muscle cells led to loss of the microtubule cytoskeleton
[14], whilst in ﬂy, C. elegans, zebraﬁsh and mouse models, loss of
spastin caused dysregulation of the microtubule network, often associ-
ated with increased or altered microtubule staining [14–19]. Beha-
vioural and anatomical phenotypes associated with depletion of
spastin in ﬂies were rescued by the microtubule destabilising drug
vinblastine, connecting the role of spastin in microtubule regulation
with in vivo phenotypes [15].
Although not yet entirely complete, our understanding of the
mechanisms by which spastin recognises and severs microtubules
has progressed signiﬁcantly. Two domains are critical, the MTBD
and the AAA ATPase. The MTBD extends from residues 270 to 328 of
human spastin, is sufﬁcient to bind to microtubules in an ATP-
independent manner, and is required for microtubule severing [20].
Microtubule breakage requires ATP hydrolysis and is catalysed by
the AAA ATPase domain, which is situated between residues 342
and 599 [1,11,21].
Structural studies of the AAA domain of Drosophila spastin have
revealed that its enzymatic core comprises a central alpha/beta
nucleotide-binding domain and a smaller four-helix bundle domain,
typical of other AAA domains [21]. However the presence of twoadditional helices that interact with the nucleotide-binding domain
differentiates spastin from other known AAA structures. These are
thought to have possible roles in allosteric control of ATP-binding
sites and substrate binding, since mutation of critical residues in
these helices impaired ATPase activity or microtubule severing activity,
or both. In the unbound state the nucleotide pocket is open, as an
extended loop involved in nucleotide contact and protomer–protomer
interactions in other AAA domain proteins is pulled away from the
nucleotide pocket. This arrangement makes ATP binding relatively
inefﬁcient [21].
A number of studies have shown that spastin, like many other AAA
ATPase proteins, can cycle between monomeric and hexameric forms,
although there is some controversy as to whether hexamerisation
requires ATP, or whether MTBD-mediated concentration of spastin on
microtubules is sufﬁcient to promote ATP-independent hexamerisation
[20–22]. Small-angle X-ray scattering studies using the AAA domain
of C. elegans spastin showed that the hexamer takes the form of a ring
with a prominent central pore of approximately 20 Å diameter [21].
The microtubule severing activity requires the acidic and disordered
approximately 20-amino acid C-terminal tail of tubulin, since when
these tails are removed by subtilisin treatment, microtubules become
resistant to severing [12]. Mutation of residues in solvent exposed
loops within the central pore also severely inhibits microtubule
severing, and it has been proposed that basic residues in these
loops are critical in binding to the C-terminal acidic tubulin tail
[21,22]. Based on these observations, two models have been proposed
to explain severing activity. Both models propose that hexameric
spastin assembles on a MT, where it is anchored by the MTBD,
and that an acidic tubulin tail projecting from the MT binds to basic
residues in the pore loop. In the dissociation model, subsequent
ATP-dependent conformational changes in the spastin hexamer
result in disruption of protomer–protomer interactions within the
microtubule, causing removal of a tubulin monomer, with subse-
quent breakdown of the MT [22]. Alternatively the translocation
model proposes that spastin destabilises MTs by using the energy
of ATP hydrolysis to unfold tubulin by fully or partially threading
it through the central pore [21].
Although these structural studies have signiﬁcantly advanced our
understanding of the mechanism MT severing by spastin, important
gaps in our knowledge remain. We do not yet know what conforma-
tional change occurs in the spastin AAA domain upon hydrolysis
of ATP, and how this translates to mechanical effects on the MT lat-
tice. In addition, we do not know whether a single spastin hexamer
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number of hexamers is required. However, recently we have begun
to understand better another important issue, concerning how MTs
are selected for severing. The C-terminal tail of tubulin can be subject
to a number of modiﬁcations, such as glutamination or tyrosination.
Interestingly, an antibody that recognises glutaminated tubulin
inhibited microtubule severing by spastin in vitro, whereas an anti-
body directed against tyrosinated tubulin did not [21]. It has recently
been shown that tubulin glutamylation, particularly polyglutamylation,
induces spastin-mediated MT severing in cultured cells, probably
by enhancing the acidity of the C-terminal tubulin tail and so strength-
ening its interaction with pore loops in the ATPase domain [23]. Thus
polyglutamination may act as a marker to allow spastin to selectively
recognise speciﬁc subsets of MTs [21,23].
These studies into the mechanism of action of spastin in microtu-
bule severing have given us important insights into the pathological
mechanism of missense mutations within the AAA domain of the pro-
tein. The majority of spastin mutations are nonsense mutations, splice
site mutations or large scale deletions, which are likely to cause dis-
ease through a haplo-insufﬁciency mechanism [24–27]. However,
missense mutations are also frequent, accounting for approximately
30% of all spastin mutations [26], and are concentrated in the AAA
ATPase domain. They could potentially impede function in several
ways, including: i) by interfering with spastin hexamerisation by
destabilising protomer–protomer interactions, ii) by preventing
ATP binding or hydrolysis, iii) by inhibiting the interaction with the
C-terminal tail of tubulin [21]. In terms of the molecular pathological
mechanism of disease, some of these mutations, for example those
that prevent the mutant spastin participating in hexamers, probably
act via effectively a haplo-insufﬁciency mechanism. However those
in which the mutant protein remains capable of hexamerisation, e.g.
ATP hydrolysis or P-loop mutants, could have a dominant negative
effect. This possibility is supported by the ﬁnding that in mammalian
cultured cells, wild-type spastin is trapped on microtubules along
with ATP hydrolysis-defective mutant spastin [28], and that in ﬂies
an ATP hydrolysis-defective mutant acts as a dominant negative
[15]. It is not yet clear whether those missense mutations that are
likely to act in a dominant negative fashion result in a more severe
disease phenotype in human HSP. In a meta-analysis of published
spastin mutants, a non-signiﬁcant trend for earlier age at onset was
found in patients with missense mutations [29]. However, this analysis
was carried out before structural information on spastin was available,
and so the missense mutants analysed were a mixture of those that
would be expected to cause haplo-insufﬁciency and those predicted to
have a dominant negative effect.
1.3. Cellular roles of MT severing
It is clear from the work summarised above that spastin is a micro-
tubule severing enzyme, and that the MTBD and AAA ATPase domain
are critical for this activity. In contrast, domains in the N-terminal
region of spastin interact with a variety of proteins that recruit spastin
to cellular sites where microtubule severing is required. Study of
these domains and their interacting proteins has given key insights
into the cellular roles of microtubule severing by spastin. The best-
characterised interacting sequences are i) the HD, which, because of
its location at the extreme N-terminal region of spastin, is only present
inM1 isoforms of spastin, and ii) theMIT domain,which is present in all
spastin isoforms. The cellular roles of spastin, mediated by interactions
with these domains, are described below.
1.3.1. The hydrophobic domain: spastin and ER shaping
TheM1 isoform of spastin, unlike M87 Spastin, is primarily localised
to the early secretory pathway, on the ER and perhaps on the early ER to
Golgi intermediate compartment [8]. A key feature of M1 spastin that
explains this localisation is the presence of the long HD that stretchesfrom residues 49 to 80. This region is predicted to form a hairpin loop
domain that partially inserts into the membrane lipid bilayer, causing
hydrophobic wedging, to generate or sense membrane curvature [30].
Similar hairpin loops are present in three interacting classes of proteins
that are found at the endoplasmic reticulum; reticulons, REEPs and
atlastins [30–33]. One function of these protein families seems to be
to shape the tubular ER. Thus, for example, in cultured cells over-
expression of reticulons causes formation of tubular ER membrane
structures, whilst deletion of yeast reticulons along with the
REEP homologue yop1p results in loss of the tubular ER [32]. Atlastins
localise to discrete sites along ER tubules, where they are required
for the formation of 3 way junctions by directly mediating the fusion
of homotypic ER tubules [31,34]. Strikingly, members of two of these
protein families, REEP1 and atlastin-1, are also HSP proteins [35,36].
M1 spastin interacts with both of these HSP proteins and with reticu-
lons at the ER, almost certainly via hydrophobic hairpin loop interac-
tions, to form what has been termed an ER morphogen complex
[30,37,38].
The precise role of spastin at the ER remains unknown. The avail-
able data are consistent with the idea that it is also an ER morphogen,
with the caveat that no requirement for endogenous spastin in ER
shaping has yet been demonstrated. Overexpression of ATPase defec-
tive M1 spastin in cultured cells results in the appearance of abnor-
mally thickened and elongated microtubule bundles [10]. In these
cells, the ER becomes highly tubular and is redistributed on to the
bundled microtubules (Fig. 2) [37]. In contrast, a collapse of the ER
network is observed in cells that are overexpressing wild-type M1
spastin (E. Reid, unpublished data). The morphology of the tubular
ER is known to be closely involved with microtubules and microtu-
bule dynamics. For example, ER tubule elongation may occur by at
least two microtubule-dependent processes, either growth by sliding
along a pre-existing microtubule track, or by attachment to a growing
microtubule plus end tip at what has been termed a tip attachment
complex [39,40]. It is clearly possible to imagine ways in which a mi-
crotubule severing protein could inﬂuence either or both of these
processes.
1.3.2. The MIT domain: spastin's roles in abscission and at endosomes
The MIT domain is found in a number of endosomal proteins,
where it is important in mediating interactions with proteins of
the CHMP (charged multivesicular body protein) family of proteins
[41,42]. CHMP family members form a complex termed ESCRT (endo-
somal sorting complex required for transport)-III, that is conserved
fromyeast toman [43]. This complex is involved inmembrane scission
during a variety of membrane modelling processes that all share
the same membrane topology of budding away from the cytosol and
cleavage from the inside face of the bud neck. These processes include
viral budding form the cell surface, inward budding of endosomal
membrane to form the internal vesicles of the late endosomal multi-
vesicular body, and the abscission stage of cytokinesis, where the
membrane bound cytoplasmic bundle which binds two daughter
cells is resolved [44–48].
In yeast, ESCRT-III comprises a core complex of 4 proteins, along
with 3 ESCRT-III associated proteins that correspond in mammalian
cells to CHMP1A and B, Ist1 and CHMP5 [43]. These ESCRT-III-
associated proteins are believed to play a regulatory role, which
includes recruitment of MIT domain-containing accessory proteins
like spastin and VPS4 (the enzyme which disassembles ESCRT-III
from membranes) to the complex, via interactions with MIT inter-
acting motifs (MIMs) in the C-terminal of speciﬁc ESCRT-III pro-
teins [41,49–53].
Spastin binds to two ESCRT-III-associated proteins, CHMP1B and
Ist1 [53–55]. The structure of the spastin-CHMP1B interaction reveals
that the spastin MIT domain consists of a three-helical bundle, and
the C-terminal helix of the CHMP1B protein binds to and ﬁlls a
groove between the ﬁrst and third helices [52]. The C-terminal half
Fig. 2. ATPase defective M1 spastin bundles microtubules and redistributes the ER onto them. M1 spastin with a disease-causing mutation (K388R) (red in the merged panel)
was expressed in HeLa cells. Microtubules are labelled in green and the endoplasmic reticulum marker calreticulin in blue in the merged panel. In the cell transfected with mutant
spastin, the ER morphology differs from the normal reticular appearance seen in adjacent untransfected cells; the ER has become more tubular, and is redistributed onto the thickened
and elongated microtubule bundles.
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teractions between hydrophobic residues and hydrophobic pockets in
the MIT. In contrast, the N-terminal half of the CHMP1B helix contrib-
utes a series of residues that participate in hydrogen bonds or van der
Waals interactions with the MIT domain. Nearly all of these residues
are unique to CHMP1B amongst the ESCRT-III proteins, and they confer
high speciﬁcity to the interaction with spastin [52]. Binding between
Ist1 and spastin has not yet been characterised structurally, although
Ist1 is known to contain twoMIMs, both ofwhich are capable of binding
MIT domains, and one of these (MIM1) is critical for the interaction
with spastin [51,53,55].
Proteins of the CHMP family exist in cytosolic,monomeric pools that
can be recruited to membranes and incorporated into the ESCRT-III
complex when the proteins are switched from an auto-inhibited
to an active state, by release of intramolecular binding between the
C-terminal helix and other sequences of the protein that are crucial
for complex polymerisation and membrane binding [56–58]. This con-
formational change also makes the C-terminal MIM motifs available
to interact with MIT domains, and consistent with this, the interaction
of spastin with a C-terminal CHMP1B fragment was stronger than the
interaction with full-length CHMP1B. This conformational change
could therefore provide a spatial and temporal trigger for interaction
with MIT-domain containing proteins [52].
The interaction between spastin and ESCRT-III associated proteins
has led to investigations of whether spastin is involved in the known
functions of ESCRT-III. The best characterised example of the func-
tional relationship between spastin and the ESCRT-III proteins is in
the ﬁnal abscission step of cytokinesis, when the microtubule-ﬁlled cy-
toplasmicmembrane bridge (midbody) that connects the two daughter
cells is broken in a process that requires both membrane remodelling
and microtubule regulation [59]. This process requires ESCRT-III and
during abscission, ESCRT-III proteins are recruited to the central
part of themembrane bridge,where they have been proposed to partic-
ipate in the development of a central constriction zone by forming con-
tractile helices composed of 17 nm ﬁlaments [60–63]. EndogenousFig. 3. Spastin-depleted cells are connected by abnormally elongated, microtubule-ﬁlled m
markers for acetylated tubulin (red) and the midbody protein aurora B (green).spastin is present in the midbody. Its recruitment there requires a func-
tional MIT domain and is signiﬁcantly reduced by cellular depletion
of CHMP1B, indicating that it is ESCRT-III-dependent [8,52]. Cellular
depletion of spastin results in failure of abscission, since the daughter
cells remain connected by greatly elongated, microtubule-ﬁlled bridges
(Fig. 3) [8,52,63]. Abscission in spastin-depleted cells can be restored
by drug-induced depolymerisation of these microtubules, indicating
that failed microtubule disassembly is the cause of the arrest
[63]. These observations have led to the proposal of a model in which
membrane constriction and eventual scission by contractile helices
composed of ﬁlaments on ESCRT-III proteins is co-ordinated with
microtubule severing by spastin, to result in complete resolution of
the cytokinetic midbody and separation of the two daughter cells
[8,52,63].
Under circumstances where polymerised ESCRT-III proteins accu-
mulate there, M87 spastin localises to endosomes in an MIT-
dependent manner [8]. Although so far no endosomal function for
spastin has been identiﬁed, studies on another endosomal protein,
protrudin (ZFYVE27), have given insights into a potential endosomal
role for spastin. Mannan and colleagues identiﬁed protrudin, a novel
member of the FYVE-ﬁnger family of proteins, as a spastin interactor
[64]. Protrudin has a number of domains of relevance to membrane
trafﬁc; a Rab11 interacting domain, two transmembrane domains,
a FAAT motif, and a FYVE C-terminal domain [65]. FYVE domains
are typically phosphatidylinositol-3-phosphate binding domains
involved in recruitment to endosomal membranes, whilst the FAAT
domain mediates interaction with the ER protein VAP-A (vesicle-
associated membrane protein associated protein) [66]. Consistent
with this, protrudin moves from the ER to endosomes during neurite
extension [65,66]. Protrudin expression induces cellular projections
in HeLa cells and neurite formation in neuronal cells, whilst loss of
protrudin inhibits neurite formation. Protrudin has been proposed
to inhibit Rab11 by binding to GDP-bound Rab11, locking it in this in-
active conformation, and so inhibiting Rab11-dependent generalised
recycling and promoting a directional membrane trafﬁc pathwayidbodies. HeLa cells were transfected with siRNA against spastin, then labelled with
196 J.H. Lumb et al. / Biochimica et Biophysica Acta 1823 (2012) 192–197required for neurite extension [65]. The role of spastin in this molecular
mechanism is unknown, however given its role in microtubule regula-
tion and membrane remodelling, spastin, protrudin and Rab11 may
constitute a system for regulating directional membrane trafﬁcking
in neurons.
In summary, most of spastin's known interactors are either mem-
brane or membrane-associated proteins, and spastin is active at sites
of membrane modelling, such as during ER shaping or in the abscis-
sion stage of cytokinesis. This suggests a view of spastin as a protein
that links the machinery of membrane modelling to microtubule
regulation by severing.1.4. Spastin and axonal degeneration
The last decade has yielded considerable advances in our under-
standing of the mechanism by which spastin severs microtubules, the
factors governing spastin's subcellular distribution, and the cellular
roles in which microtubule severing by spastin is important. However,
many questions remain, particularly in relation to the mechanism by
which abnormality of spastin causes axonal degeneration.
Mice lacking spastin develop axonal swellings and defects in
both anterograde and retrograde axonal transport, accompanied by
MT abnormalities at the distal axon [17,67]. In patients with spastin
gene mutations, HSP probably develops because the normal functions
of the protein cannot be accomplished, in the case of haplo-
insufﬁciency mutations because the concentration of the protein is too
low, and in the case of some missense mutations because the mutant
spastin exerts dominant negative effects. However, we do not yet
know, in mice or in man, whether the axonopathy associated with mu-
tation of spastin is caused by defects in the cellular functions of the
M1 isoform, the M87 isoform, or a mixture of both. Analysis of patient
mutations has not been helpful in this respect, since all spastin muta-
tions identiﬁed to date could potentially affect both isoforms; evenmu-
tations in exon 1 that might be expected only to affect the M1 isoform
could also affect the M87 isoform by disrupting the cryptic promotor
in exon1 that controls transcription of the M87 spastin-speciﬁc mRNA
[7]. The simplest explanation for the involvement of 3 HSP proteins,
including M1 spastin, in membrane shaping at the ER is that abnormal-
ity of this process leads directly to the disease, and this would suggest
that it is the M1 isoform that is pathogenic. In keeping with this, the
M1 isoform has higher expression in spinal cord than in other tissues
[6,68]. However, since M1 and M87 spastin could theoretically partici-
pate in hexamers together, other interpretations are also possible;
it is conceivable that some abnormalities of the ER morphogen com-
plex might sequester M87 spastin from its normal sites of action,
so affecting, for example, endosomal functions of spastin. This would
be consistent with the fact that many other HSP proteins localise to
endosomes, suggesting that endosomal function can be important in
the development of HSP [5]. This issue needs to be addressed, perhaps
by examining whether axonopathy develops in animal models lacking
only one of the spastin isoforms.
We also do not yet have a clear understanding of how abnormali-
ties in the known cellular functions of spastin could cause axonopathy.
Considering ER-shaping, the axon contains abundant smooth ER tu-
bules, which have been implicated in cholesterol and lipid metabo-
lism, as well as in Ca2+ regulation, and further work is required to
examine whether abnormal ER shaping in the axon can lead to dys-
function of these processes [69]. The axon also contains an extensive
endosomal compartment that has important roles in synaptic growth
and plasticity, as well as in regulating axonal signalling pathways,
and spastin abnormality could potentially affect these processes. In-
deed, abnormal axonal bonemorphogenetic protein (BMP) signalling,
caused in a least some cases by altered BMP receptor endosomal traf-
ﬁcking, has been found in cellular and non-mammalian animalmodels
of some forms of HSP, including cellular models of spastin HSP [70–72]. The relevance of these ﬁndings to HSP pathogenesis requires
conﬁrmation in mammalian in vivo models.
Finally, a difﬁcult question to address is whether, under physiolog-
ical conditions within cells, spastin requires to be concentrated by
adaptor proteins in order for oligomerisation and subsequent enzy-
matic activity to occur, as has been suggested for another AAA ATPase
from the same family, VPS4 [73]. In vitro studies with puriﬁed compo-
nents have shown that microtubule severing can occur independent
of adaptor proteins (see above) and transient over-expression of
spastin constructs lacking the N-terminal adaptor protein binding
domains still results in microtubule severing in cultured cells [20],
but of course these are non-physiological systems. The answer
to this question is important, since it will help determine whether
spastin abnormality could cause axonopathy simply by causing a
general disruption of microtubule regulation, or instead whether
the primary defect is focused on microtubules related to the speciﬁc
pathways targeted by spastin adaptors.
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